LATEST
CM Lays Stone For Works Worth Rs 3,222 Crore In Tirupati✦Cooper Flagg’s link-up with David Beckham after Mavericks preseason game draws attention✦Ira Winderman: Bam Adebayo, Giannis Antetokounmpo present staggering (and staggered) possibilities for Heat✦Former Grenfell Tower housing boss leaves £150,000 council property role after backlash✦DMK Leader Elangovan Calls Actor Vijay Slave of BJP; Slams Centre Over Keezhadi✦
Mon, Oct 12, 2026
Loading weather...
Markets

BridgeBio Reports Encaleret Gains In ADH1; Starts RECLAIM-HP Phase 3 In Chronic Hypoparathyroidism

(RTTNews) - On Sunday, BridgeBio Pharma, Inc. (BBIO), a biopharmaceutical company, presented additional Phase 3 data for...

By Dhallo News · October 12, 2026 at 12:36 PM IST

(RTTNews) - On Sunday, BridgeBio Pharma, Inc. (BBIO), a biopharmaceutical company, presented additional Phase 3 data for Encaleret in autosomal dominant hypocalcemia type 1. The findings were presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meet

SOURCE: Nasdaq
ORIGINAL REPORT: Click here
DHALLO EDITORIAL STATUS: Aggregated & reviewed
Have feedback on this article?Report error or suggestion

Read More from Markets

Retail stocks to buy before Q2 results: Metro Brands, Campus Activewear, Vishal Mega Mart shares — Elara recommends

Elara Securities expects India’s retail sector to post 11.8% revenue growth in Q...

Read Article »

Odd Lots: Nate Soares on How AI Could Kill Us All (Podcast)

Since the Hugging Face incident, concerns over AI doomsday scenarios has entered...

Read Article »

Stellantis CEO Says Company Split 'Not Plausible'

Stellantis Chief Executive Officer Antonio Filosa says a Europe-US split of the ...

Read Article »
Return to Front Page

5 minutes. The news that matters.

Get the most important stories of the day, without having to browse hundreds of articles.